Dalbavancin

Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacter...

Descripción completa

Detalles Bibliográficos
Autores principales: Barberán, José, de la Cuerda, Alicia, Barberán, Lourdes Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2021
Materias:
Update on Antimicrobial Pharmacotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683005/
https://www.ncbi.nlm.nih.gov/pubmed/34598419
http://dx.doi.org/10.37201/req/s01.07.2021
_version_ 1784617324857262080
author Barberán, José
de la Cuerda, Alicia
Barberán, Lourdes Cristina
author_facet Barberán, José
de la Cuerda, Alicia
Barberán, Lourdes Cristina
author_sort Barberán, José
collection PubMed
description Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacterial skin and skin structure infections (ABSSSIs), but in real-life clinical practice it has already been used successfully and safely in other infections, especially as consolidation therapy.
format Online
Article
Text
id pubmed-8683005
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-86830052021-12-29 Dalbavancin Barberán, José de la Cuerda, Alicia Barberán, Lourdes Cristina Rev Esp Quimioter Update on Antimicrobial Pharmacotherapy Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacterial skin and skin structure infections (ABSSSIs), but in real-life clinical practice it has already been used successfully and safely in other infections, especially as consolidation therapy. Sociedad Española de Quimioterapia 2021-09-30 2021 /pmc/articles/PMC8683005/ /pubmed/34598419 http://dx.doi.org/10.37201/req/s01.07.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Update on Antimicrobial Pharmacotherapy
Barberán, José
de la Cuerda, Alicia
Barberán, Lourdes Cristina
Dalbavancin
title Dalbavancin
title_full Dalbavancin
title_fullStr Dalbavancin
title_full_unstemmed Dalbavancin
title_short Dalbavancin
title_sort dalbavancin
topic Update on Antimicrobial Pharmacotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683005/
https://www.ncbi.nlm.nih.gov/pubmed/34598419
http://dx.doi.org/10.37201/req/s01.07.2021
work_keys_str_mv AT barberanjose dalbavancin
AT delacuerdaalicia dalbavancin
AT barberanlourdescristina dalbavancin

Ejemplares similares